2019
DOI: 10.1016/j.prp.2019.152479
|View full text |Cite
|
Sign up to set email alerts
|

Xp11.2 translocation renal cell carcinoma with SFPQ/PSF-TFE3 fusion gene: A case report with unusual histopathologic findings

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(3 citation statements)
references
References 19 publications
0
3
0
Order By: Relevance
“…In previously reported literature, ASPSCR1/ASPL-TFE3 and PRCC-TFE3 were the most frequently detected partner genes, followed by SFPQ/PSF-TFE3, NONO-TFE3, CLTC-TFE3, while other partner genes such as RMB10-TFE3, DVL2-TFE3, etc. are rarely reported ( 5 ). Most patients with Xpl1.2 RCC have no clinical manifestations, and only a small number of patients may present with gross hematuria, lower back pain, and abdominal mass, which are defined as the renal cancer triad.…”
Section: Discussionmentioning
confidence: 99%
“…In previously reported literature, ASPSCR1/ASPL-TFE3 and PRCC-TFE3 were the most frequently detected partner genes, followed by SFPQ/PSF-TFE3, NONO-TFE3, CLTC-TFE3, while other partner genes such as RMB10-TFE3, DVL2-TFE3, etc. are rarely reported ( 5 ). Most patients with Xpl1.2 RCC have no clinical manifestations, and only a small number of patients may present with gross hematuria, lower back pain, and abdominal mass, which are defined as the renal cancer triad.…”
Section: Discussionmentioning
confidence: 99%
“…112 Other fusion subtypes are rare and have limited reported follow-up. 16,126,150,153 Gross and Microscopic Findings Grossly, Xp11.2 translocation RCC can be indistinguishable from clear cell renal cell carcinoma (CCRCC). 18,123,131 Smaller lesions tend to be well-circumscribed, whereas larger lesions may be infiltrative and extend outside the kidney.…”
Section: Clinical Findings and Prognosismentioning
confidence: 99%
“…NONO , SFPQ , GRIPAP1 , and MED15 cases have been predominantly low stage, but rare metastatic cases have been documented 112. Other fusion subtypes are rare and have limited reported follow-up 16,126,150,153…”
Section: Malignant Renal Neoplasmsmentioning
confidence: 99%